Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to evaluate the efficacy of secukinumab (300mg) treatment with respect to PASI 75 response rate after 16 weeks treatment, by assessing the percentage (%) of patients achieving PASI 75 after 16 weeks compared to baseline (defined as PASI status at Week 0).
Critère d'inclusion
- Moderate to severe active, chronic plaque psoriasis